RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clovis Oncology - Stock

Clovis Oncology ROCE 2024

Clovis Oncology ROCE

0.79

Clovis Oncology Dividend yield

Ticker

C6O.F

ISIN

US1894641000

WKN

A1JPJY

In 2024, Clovis Oncology's return on capital employed (ROCE) was 0.79, a 0% increase from the 0 ROCE in the previous year.

Clovis Oncology Aktienanalyse

What does Clovis Oncology do?

Clovis Oncology Inc. is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. The company is based in Boulder, Colorado and was founded in 2009. They focus on researching and developing innovative therapies for cancer patients. History: Clovis Oncology was founded by Patrick Mahaffy and his team, who previously worked at Pharmion Corporation and sold the biotech company to Celgene. After the sale of Pharmion, Mahaffy and his colleagues wanted to build something new and started Clovis Oncology. Clovis started its activities in 2009 and initially focused on the development of PARP inhibitors, which can be used for the treatment of breast and ovarian cancer. In 2011, the company conducted Phase I studies with its leading product candidate, Rucaparib. Business model: Clovis Oncology has a business model based on the discovery, development, and commercialization of innovative cancer therapies. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a global network of research and development facilities that allows them to focus on the therapy areas where they are best positioned. Through partnerships and licenses, the company also has access to specialized technologies and expertise in cancer research. Divisions: Clovis Oncology is divided into two divisions: 1. Research and development: Clovis operates an intensive research and development program focused on the discovery and development of new cancer therapies. The focus is on developing PARP inhibitors that offer new treatments for breast and ovarian cancer. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a strong pipeline of products in various stages of clinical development. 2. Commercialization: Clovis also has an experienced marketing team responsible for the marketing and distribution of Rucaparib. Rucaparib is a PARP inhibitor approved for the treatment of breast and ovarian cancer in the United States and several other countries. Products: The main product of Clovis Oncology is Rucaparib, a PARP inhibitor for the treatment of breast and ovarian cancer. The medication was approved by the US Food and Drug Administration (FDA) in December 2016 for use in patients with advanced ovarian cancer. Clovis also has a pipeline of products in various stages of clinical development. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Summary: Clovis Oncology is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. They have a focus on developing PARP inhibitors and currently offer Rucaparib for the treatment of breast and ovarian cancer. Clovis has a strong pipeline of products in various stages of clinical development and collaborates closely with academic institutions and other companies to advance cancer research. Clovis Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Clovis Oncology's Return on Capital Employed (ROCE)

Clovis Oncology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Clovis Oncology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Clovis Oncology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Clovis Oncology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Clovis Oncology Stock

What is the ROCE (Return on Capital Employed) of Clovis Oncology this year?

The ROCE of Clovis Oncology is 0.79 undefined this year.

How has the ROCE (Return on Capital Employed) of Clovis Oncology developed compared to the previous year?

The ROCE of Clovis Oncology has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Clovis Oncology?

A high Return on Capital Employed (ROCE) indicates that Clovis Oncology has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Clovis Oncology?

A low ROCE (Return on Capital Employed) can indicate that Clovis Oncology has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Clovis Oncology impact the company?

An increase in the ROCE of Clovis Oncology can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Clovis Oncology affect the company?

A decrease in ROCE of Clovis Oncology can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Clovis Oncology?

Some factors that can affect Clovis Oncology's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Clovis Oncology so important for investors?

The ROCE of Clovis Oncology is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Clovis Oncology take to improve the ROCE?

To improve the ROCE, Clovis Oncology can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Clovis Oncology pay?

Over the past 12 months, Clovis Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clovis Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Clovis Oncology?

The current dividend yield of Clovis Oncology is .

When does Clovis Oncology pay dividends?

Clovis Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clovis Oncology?

Clovis Oncology paid dividends every year for the past 0 years.

What is the dividend of Clovis Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clovis Oncology located?

Clovis Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clovis Oncology from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Clovis Oncology pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Clovis Oncology in the year 2023?

In the year 2023, Clovis Oncology distributed 0 USD as dividends.

In which currency does Clovis Oncology pay out the dividend?

The dividends of Clovis Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Clovis Oncology stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Clovis Oncology

Our stock analysis for Clovis Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clovis Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.